Rigorous manufacturing and control processes
Impryl is manufactured at a facility in the United States that is regularly inspected by NSF International, the United States Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA). These inspectional activities ensure that the facility is operating according to contemporary manufacturing and quality standards, including 21 CFR Part 111 Current Good Manufacturing Practice in Manufacturing, Packaging Labeling, or Holding Operations for Dietary Supplements. Adherence to these strict standards allows you to use Impryl with confidence for your supplementation needs.
Material Verification
Prior to use in the manufacture of Impryl, all starting materials – micronutrients, inactive ingredients and capsules alike – are verified to ensure identity and conformity to the material-specific certificate of analysis.
In-Process Controls
During the blending and encapsulation steps, product samples are taken and analyzed to confirm that the process is performing as expected. If needed, adjustments are made to ensure product quality.
Laboratory Testing
After bottling, Impryl capsules are laboratory tested for 23 independent parameters. The resulting data must meet acceptance criteria established by the United States Pharmacopeia (USP) to be released for sale.